drugset / Trial / NCT00659659

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659

Phase 1 Completed 27 enrolled MedImmune LLC
RandomizedSingle-groupDouble-blindTreatment

Summary

Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies

Timeline

Start
2008-01
Primary completion
2011-01
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody 1 mg/kg Intravenous
Subject Benralizumab Monoclonal antibody 100 mg Intravenous
Subject Benralizumab Monoclonal antibody 200 mg Intravenous

Indications